A Phase I Study of a p53MVA Vaccine in Combination With Pembrolizumab

Trial Profile

A Phase I Study of a p53MVA Vaccine in Combination With Pembrolizumab

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs MVA-p53 (Primary) ; Pembrolizumab
  • Indications Bladder cancer; Breast cancer; Colorectal cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Mar 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
    • 09 Jan 2017 Planned number of patients changed from 12 to 19.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top